Clinical Trials Browser

Phase 1/2 × Hodgkin Disease × Alemtuzumab × Clear all

NCT02059239 2021-02-21

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Phase 1/2 Completed

34 enrolled 22 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Phase 1/2 Terminated

3 enrolled 15 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

NCT00520130 2019-03-05

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Phase 1/2 Completed

92 enrolled 28 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes

NCT00056966 2012-06-29

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Phase 1/2 Completed

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma